RATIONALE: Ventricular fibrillation (VF) leads to global ischemia. The modulation of ischemia-dependent pathways may alter the electrophysiological evolution of VF. OBJECTIVE: We addressed the hypotheses that there is regional disease-related expression of K(ATP) channels in human cardiomyopathic hearts and that K(ATP) channel blockade promotes spontaneous VF termination by attenuating spatiotemporal dispersion of refractoriness. METHODS AND RESULTS: In a human Langendorff model, electric mapping of 6 control and 9 treatment (10 μmol/L glibenclamide) isolated cardiomyopathic hearts was performed. Spontaneous defibrillation was studied and mean VF cycle length was compared regionally at VF onset and after 180 seconds between control and treatment groups. K(ATP) subunit gene expression was compared between LV endocardium versus epicardium in myopathic hearts. Spontaneous VF termination occurred in 1 of 6 control hearts and 7 of 8 glibenclamide-treated hearts (P=0.026). After 180 seconds of ischemia, a transmural dispersion in VF cycle length was observed between epicardium and endocardium (P=0.001), which was attenuated by glibenclamide. There was greater gene expression of all K(ATP) subunit on the endocardium compared with the epicardium (P<0.02). In an ischemic rat heart model, transmural dispersion of refractoriness (ΔERP(Transmural)=ERP(Epicardium)-ERP(Endocardium)) was verified with pacing protocols. ΔERP(Transmural) in control was 5 ± 2 ms and increased to 36 ± 5 ms with ischemia. This effect was greatly attenuated by glibenclamide (ΔERP(Transmural) for glibenclamide+ischemia=4.9 ± 4 ms, P=0.019 versus control ischemia). CONCLUSIONS: K(ATP) channel subunit gene expression is heterogeneously altered in the cardiomyopathic human heart. Blockade of K(ATP) channels promotes spontaneous defibrillation in cardiomyopathic human hearts by attenuating the ischemia-dependent spatiotemporal heterogeneity of refractoriness during early VF.
RATIONALE: Ventricular fibrillation (VF) leads to global ischemia. The modulation of ischemia-dependent pathways may alter the electrophysiological evolution of VF. OBJECTIVE: We addressed the hypotheses that there is regional disease-related expression of K(ATP) channels in humancardiomyopathic hearts and that K(ATP) channel blockade promotes spontaneous VF termination by attenuating spatiotemporal dispersion of refractoriness. METHODS AND RESULTS: In a human Langendorff model, electric mapping of 6 control and 9 treatment (10 μmol/L glibenclamide) isolated cardiomyopathic hearts was performed. Spontaneous defibrillation was studied and mean VF cycle length was compared regionally at VF onset and after 180 seconds between control and treatment groups. K(ATP) subunit gene expression was compared between LV endocardium versus epicardium in myopathic hearts. Spontaneous VF termination occurred in 1 of 6 control hearts and 7 of 8 glibenclamide-treated hearts (P=0.026). After 180 seconds of ischemia, a transmural dispersion in VF cycle length was observed between epicardium and endocardium (P=0.001), which was attenuated by glibenclamide. There was greater gene expression of all K(ATP) subunit on the endocardium compared with the epicardium (P<0.02). In an ischemicrat heart model, transmural dispersion of refractoriness (ΔERP(Transmural)=ERP(Epicardium)-ERP(Endocardium)) was verified with pacing protocols. ΔERP(Transmural) in control was 5 ± 2 ms and increased to 36 ± 5 ms with ischemia. This effect was greatly attenuated by glibenclamide (ΔERP(Transmural) for glibenclamide+ischemia=4.9 ± 4 ms, P=0.019 versus control ischemia). CONCLUSIONS: K(ATP) channel subunit gene expression is heterogeneously altered in the cardiomyopathichuman heart. Blockade of K(ATP) channels promotes spontaneous defibrillation in cardiomyopathichuman hearts by attenuating the ischemia-dependent spatiotemporal heterogeneity of refractoriness during early VF.
Authors: Lizhi Xu; Sarah R Gutbrod; Andrew P Bonifas; Yewang Su; Matthew S Sulkin; Nanshu Lu; Hyun-Joong Chung; Kyung-In Jang; Zhuangjian Liu; Ming Ying; Chi Lu; R Chad Webb; Jong-Seon Kim; Jacob I Laughner; Huanyu Cheng; Yuhao Liu; Abid Ameen; Jae-Woong Jeong; Gwang-Tae Kim; Yonggang Huang; Igor R Efimov; John A Rogers Journal: Nat Commun Date: 2014-02-25 Impact factor: 14.919
Authors: Li Lu; Shuyu Ye; Rebecca L Scalzo; Jane E B Reusch; Clifford R Greyson; Gregory G Schwartz Journal: Diabetologia Date: 2017-05-11 Impact factor: 10.122
Authors: Paco E Bravo; Stefan L Zimmerman; Hong-Chang Luo; Iraklis Pozios; Mahadevan Rajaram; Aurélio Pinheiro; Charles Steenbergen; Ihab R Kamel; Richard L Wahl; David A Bluemke; Frank M Bengel; M Roselle Abraham; Theodore P Abraham Journal: Circ Cardiovasc Imaging Date: 2013-02-15 Impact factor: 7.792
Authors: Tyson G Taylor; Paul W Venable; Junko Shibayama; Mark Warren; Alexey V Zaitsev Journal: Am J Physiol Heart Circ Physiol Date: 2012-03-30 Impact factor: 4.733
Authors: Charles E Leonard; Sean Hennessy; Xu Han; David S Siscovick; James H Flory; Rajat Deo Journal: Trends Endocrinol Metab Date: 2017-05-22 Impact factor: 12.015
Authors: Byron N Roberts; Pei-Chi Yang; Steven B Behrens; Jonathan D Moreno; Colleen E Clancy Journal: Am J Physiol Heart Circ Physiol Date: 2012-08-10 Impact factor: 4.733